Semprex-D

Sneezing, Chronic Pain, Catarrh + 31 more

Treatment

1 FDA approval

20 Active Studies for Semprex-D

Treatment for

Sneezing

What is Semprex-D

Pseudoephedrine

The Generic name of this drug

Treatment Summary

Pseudoephedrine is a drug related to ephedrine, which is found in the ephedra plant. It was first studied in the West in 1889, and later found to have a weaker effect on the sympathetic nervous system than ephedrine. In 1927, Pseudoephedrine was identified as a decongestant for dogs.

Nasal Decongestant Maximum Strength

is the brand name

image of different drug pills on a surface

Semprex-D Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Nasal Decongestant Maximum Strength

Pseudoephedrine

1981

547

Approved as Treatment by the FDA

Pseudoephedrine, also known as Nasal Decongestant Maximum Strength, is approved by the FDA for 1 uses including Nasal Congestion .

Nasal Congestion

Effectiveness

How Semprex-D Affects Patients

Pseudoephedrine causes blood vessels to narrow, which helps clear a stuffy nose. This effect does not last very long, unless it is taken in an extended release form. Taking it also carries the risk of stimulating the central nervous system.

How Semprex-D works in the body

Pseudoephedrine works by stimulating certain adrenergic receptors, which causes blood vessels to constrict. This makes it useful for treating blocked sinuses and other congestions, as well as for treating erectile dysfunction. Pseudoephedrine also increases blood pressure, heart rate, and the response of the right atria. It can also partially activate the anococcygeal muscle. Finally, pseudoephedrine can block certain proteins involved in inflammation.

When to interrupt dosage

The recommended measure of Semprex-D is contingent upon the indicated condition, such as Upper Respiratory Tract Infection, Airway secretion clearance therapy and Coughing. The measure of dosage is dependent on the technique of administration (e.g. Tablet, extended release or Oral) provided in the accompanying table.

Condition

Dosage

Administration

Catarrh

60.0 mg, , 120.0 mg, 240.0 mg, 30.0 mg, 6.0 mg/mL, 3.0 mg/mL, 15.0 mg/mL, 30.0 mg/mL, 60.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 40.0 mg, 50.0 mg/mL, 14.998 mg/mL, 15.001 mg/mL, 0.3 mg/mg, 0.15 mg/mg, 7.5 mg/mL, 25.0 mg, 45.0 mg/mL, 15.0 mg, 7.5 mg, 9.38 mg/mL, 20.0 mg, 45.0 mg, 4.0 mg/mL, 80.0 mg, 4.5 mg/mL, 22.5 mg/mL, 14.999 mg/mL, 9.0 mg/mL, 8.0 mg/mL, 12.5 mg/mL, 25.0 mg/mL, 180.0 mg, 0.6 mg/mg, 75.0 mg/mL, 0.06 mg/mg, 0.006 mg/mg

Oral, Powder, for solution - Oral, , Powder, for solution, Tablet, extended release, Tablet, extended release - Oral, Tablet, film coated - Oral, Tablet, film coated, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Tablet, sugar coated, Tablet, sugar coated - Oral, Capsule, liquid filled - Oral, Capsule, liquid filled, Tablet, coated, Liquid - Oral, Tablet, coated - Oral, Liquid, Tablet, Tablet - Oral, Solution, Solution - Oral, Syrup - Oral, Syrup, Elixir, Elixir - Oral, Solution / drops, Solution / drops - Oral, Capsule - Oral, Capsule, Suspension, Suspension - Oral, Pill, Pill - Oral, Tablet, multilayer - Oral, Tablet, multilayer, Powder - Oral, Capsule, extended release - Oral, Capsule, extended release, Powder, Tablet, chewable, Tablet, chewable - Oral, Kit; Tablet - Oral, Tablet; Tablet, extended release - Oral, Tablet; Tablet, extended release, Kit; Tablet, Tablet, multilayer, extended release, Tablet, multilayer, extended release - Oral, Capsule; Kit, Capsule; Kit - Oral, Kit; Powder - Oral, Kit; Powder, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Kit; Powder, for solution - Oral, Kit; Powder, for solution, Kit, Kit - Oral, Solution / drops - Nasal, Nasal, Tablet, for suspension - Oral, Tablet, for suspension

Priapism

Migraine

Bronchitis

Fever

Upper respiratory tract signs and symptoms

Influenza

Rhinitis, Allergic

Sneezing

Acute Bronchitis

Chronic Pain

Throat irritation

Sinusitis

Upper respiratory tract congestion

Rhinorrhea

Sinus Congestion

Coughing

Pharyngitis

Common Cold

Hypersensitivity

Warnings

Semprex-D Contraindications

Condition

Risk Level

Notes

Coronary Artery Disease

Do Not Combine

Hypertension

Do Not Combine

Urinary Retention

Do Not Combine

Pulse Frequency

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Pseudoephedrine may interact with Pulse Frequency

There are 20 known major drug interactions with Semprex-D.

Common Semprex-D Drug Interactions

Drug Name

Risk Level

Description

Iobenguane

Major

Pseudoephedrine can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.

Methylene blue

Major

Pseudoephedrine may increase the serotonergic activities of Methylene blue.

Mirtazapine

Major

Pseudoephedrine may increase the serotonergic activities of Mirtazapine.

1-benzylimidazole

Minor

The therapeutic efficacy of 1-benzylimidazole can be decreased when used in combination with Pseudoephedrine.

4-Methoxyamphetamine

Minor

The risk or severity of hypertension can be increased when Pseudoephedrine is combined with 4-Methoxyamphetamine.

Semprex-D Toxicity & Overdose Risk

The lowest toxic dose of pseudoephedrine in rats has been found to be 2206mg/kg, and 726mg/kg in mice. Overdosing on pseudoephedrine may cause dizziness, headaches, nausea, vomiting, excessive sweating, increased heart rate, chest pain, difficulty urinating, muscle weakness, tension, anxiety, restlessness, insomnia, confusion, irregular heartbeat, circulation collapse, seizures, loss of consciousness, and breathing problems. Treatment for overdose involves providing relief from symptoms and getting rid of any unabsorbed drug.

image of a doctor in a lab doing drug, clinical research

Semprex-D Novel Uses: Which Conditions Have a Clinical Trial Featuring Semprex-D?

Currently, 270 active clinical trials are examining the potential of Semprex-D to alleviate Allergies, Migraines and Ocular Irritations.

Condition

Clinical Trials

Trial Phases

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Sinus Congestion

0 Actively Recruiting

Throat irritation

0 Actively Recruiting

Hypersensitivity

1 Actively Recruiting

Phase 4

Acute Bronchitis

7 Actively Recruiting

Phase 4, Not Applicable, Phase 3, Early Phase 1

Sneezing

0 Actively Recruiting

Migraine

13 Actively Recruiting

Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4

Pharyngitis

0 Actively Recruiting

Bronchitis

0 Actively Recruiting

Sinusitis

2 Actively Recruiting

Not Applicable

Influenza

29 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 1, Phase 3

Hay Fever

0 Actively Recruiting

Rhinorrhea

0 Actively Recruiting

Seasonal Allergies

0 Actively Recruiting

Fever

2 Actively Recruiting

Not Applicable, Phase 4

Perennial Allergy

0 Actively Recruiting

Coughing

0 Actively Recruiting

Common Cold

0 Actively Recruiting

Eye

0 Actively Recruiting

Coughing

0 Actively Recruiting

Semprex-D Reviews: What are patients saying about Semprex-D?

Patient Review

12/7/2007

Semprex-D for Stuffy Nose

I've been taking this medication for ten years, and it's really helped me a lot. If I forget to take it, I start sneezing uncontrollably and my nose starts running.

Patient Review

7/23/2012

Semprex-D for Stuffy Nose

I've been using Semprex D for my allergies for over two decades, and it's really helped me out. I only need one capsule most mornings, but if I'm working outdoors or around cigarette smoke, I'll take another one. It's definitely decreased how often I need it since my sinus surgery, but it's still a helpful medication when needed.

Patient Review

1/11/2012

Semprex-D for Non-Seasonal Allergic Runny Nose

Semprex-D is quite expensive, even when taking advantage of Medicare Part D's mail order program. I am hoping it will become available as a generic soon so that I can afford it again.

Patient Review

11/11/2009

Semprex-D for Allergic Conjunctivitis

I've tried a lot of different allergy medications, and Semprex D is by far the most effective one I've found.

Patient Review

6/5/2009

Semprex-D for Inflammation of the Nose due to an Allergy

Nonseasonal allergies. Headache & sinus pressure go away - sometimes replaced by a runny nose, but it's better than the headache.

Patient Review

12/28/2010

Semprex-D for Allergic Conjunctivitis

I used to use Sempea-D for my fluid buildup issue, but it's become too expensive. I was told that clemastine fumarate along with Sudafed would be a suitable replacement, but I'm not sure if that's true.

Patient Review

1/15/2012

Semprex-D for Non-Seasonal Allergic Runny Nose

Semprex-D has been a godsend for me. It really helps to take care of my allergies and I notice that when I don't use it, my symptoms get worse.

Patient Review

2/1/2017

Semprex-D for Allergic Conjunctivitis

Though it's expensive, this is the only allergy medication that works for me. Unfortunately, my insurance will no longer cover the cost.

Patient Review

12/3/2007

Semprex-D for Inflammation of the Nose due to an Allergy

3.3

Patient Review

12/30/2011

Semprex-D for Seasonal Runny Nose

This medication helped with my sinus problems, but unfortunately also made me feel very dizzy and nauseous.

image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about semprex-d

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has Semprex-d been discontinued?

"Semprex-D, a combination of two medications used to treat allergy symptoms such as runny or stuffy nose, sneezing, and itchy eyes, is no longer available in the United States."

Answered by AI

What is Semprex-D used for?

"Decongestants help to reduce swelling and congestion in the nose.

This medication is used to relieve symptoms of the common cold, flu, allergies, or other breathing illnesses. It contains antihistamines to relieve watery eyes, itchy eyes/nose/throat, runny nose, and sneezing. It also contains decongestants to reduce swelling and congestion in the nose."

Answered by AI

Is Symdex a cold?

"This medication is used to help relieve symptoms associated with colds, headaches, allergic rhinitis, and sinusitis."

Answered by AI

What are the ingredients in Semprex-D?

"The medication Acrivastine contains both an antihistamine and a decongestant. Each capsule contains 8 mg of acrivastine and 60 mg of pseudoephedrine hydrochloride. The inactive ingredients in the capsules are lactose, magnesium stearate, and sodium starch glycolate."

Answered by AI

Clinical Trials for Semprex-D

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+

All Sexes

Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting

Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Image of Alberta Children's Hospital in Calgary, Canada.

Therapeutic Cuddling for Pain in Critically Ill Children

< 65

All Sexes

Calgary, Canada

2.1 CONTEXT Pain and agitation are common comorbidities of pediatric critical illness due to both underlying disease processes and ICU related therapies. These are associated with both short and long term negative sequelae including increased mortality, length of stay, rates of ICU delirium, worse sleep, increased anxiety, depression, and chronic pain. The current standard of care to manage PICU associated pain and agitation is the use of analgosedation (e.g. opioids and benzodiazepines) these too are associated with increased time on the ventilator, length of stay, ICU delirium, and long term mental health and negative neuro-cognitive outcomes. Despite recommendations for increased use of non-pharmacologic therapies in the prevention and management of PICU associated pain, agitation, delirium, and analgosedation exposure, there are currently know therapies with clear evidence of efficacy. Therapeutic cuddling (e.g. kangaroo care, clothed cuddling, comfort holding, etc.) has been shown to decrease pain and anxiety in critically ill neonates, and healthy children and adults. Positive affective touch and hugging has known physiologic benefits and has been associated with decreased pain, improved immunity, and decreased mortality. Despite the potential for this intervention to aid in the prevention and management of PICU associated pain, agitation, delirium and analgosedation exposure, little data exists on efficacy of therapeutic cuddling in critically ill children. 2.2 OBJECTIVES 2.2.1 Primary Determine the feasibility of screening, consent, randomization, and retention of participants in a pragmatic RCT of therapeutic cuddling versus standard of care in the Alberta Children's Hospital Pediatric Intensive Care Unit. 2.2.2 Secondary 1. Determine treatment fidelity of participants randomized to the intervention arm. 2. Determine the prevalence of the therapeutic cuddling intervention in those randomized to the standard of care arm. 3. Determine the feasibility of measurement of key outcomes and co-variates (i.e., pain, agitation, sedation, delirium, analgosedation exposure, parental presence). 4. Describe the experience of patients, caregivers, and healthcare professionals in delivering/receiving the therapeutic cuddling intervention. 2.3 STUDY DESIGN Pilot feasibility randomized controlled trial of a structured co-designed therapeutic cuddling intervention as compared to the standard of care in a single tertiary care PICU. 2.4 DURATION 6 months to 1 year 2.5 LOCATION, DEPARTMENTS, AND FACILITY WHERE RESEARCH WILL BE UNDERTAKEN The pediatric intensive care unit at the Alberta Children's Hospital 2.6 SAMPLE SIZE A total sample size of 112 participants (56 per arm)

Recruiting

Has No Placebo

Alberta Children's Hospital